Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) serve as key biomarkers in breast cancer, and their expression in tumor cells forms the basis for endocrine therapy, targeted therapy and disease prognosis. This evidence concerns the gene ESR1 and breast cancer.